

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS

El último caso con poliovirus salvaje fue detectado el 5 de septiembre de 1991, en Perú

Vigilancia de la Poliomielitis en las Américas

Cuadro No.1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2011/42 - 2012/41)

| Lab. | País | Total ¹ | SIN RESULTADOS | | | | AISLAMIENTO DE VIRUS | | | | | | | | |
|--------------|------------------|--------------------|----------------|----------|------------|-----------|-------------------------|-------------|-------------------|-------------|------------|-----------|--------------------|----------|----------|
| | | | Aún no en lab. | ≤14 días | 15-21 días | >21 días | % Aislamiento | Negativo | Otros Enterovirus | Otros Virus | Poliovirus | | | | |
| | | | | | | | | | | | Pendiente | Vacunal | Derivado de vacuna | Salvaje | |
| CAR | DOM | 21 | 1 | 0 | 0 | 0 | 15.0 | 17 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| | GUY | 3 | 0 | 0 | 0 | 3 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | HND | 66 | 3 | 0 | 0 | 1 | 17.7 | 51 | 10 | 1 | 0 | 0 | 0 | 0 | 0 |
| | HTI | 6 | 6 | 0 | 0 | 0 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | JAM | 5 | 0 | 0 | 0 | 5 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | NIC | 29 | 3 | 0 | 0 | 0 | 19.2 | 21 | 4 | 0 | 1 | 0 | 0 | 0 | 0 |
| | PAN | 5 | 0 | 0 | 0 | 0 | 0.0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | SLV | 1 | 0 | 0 | 0 | 0 | 0.0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CDC | GTM | 52 | 3 | 0 | 0 | 1 | 20.8 | 38 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| | HND | 1 | 1 | 0 | 0 | 0 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | NIC | 1 | 0 | 0 | 0 | 0 | 100.0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | PRY | 14 | 1 | 0 | 0 | 1 | 25.0 | 10 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| | SLV | 24 | 7 | 0 | 0 | 3 | 14.3 | 11 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| FIO | BRA | 295 | 56 | 0 | 0 | 2 | 8.0 | 218 | 12 | 0 | 0 | 7 | 0 | 0 | 0 |
| | PER | 95 | 3 | 0 | 0 | 0 | 10.9 | 82 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| IEC | BRA | 53 | 4 | 0 | 0 | 3 | 0.0 | 46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| INDRE | MEX ² | 333 | 45 | 8 | 0 | 5 | 7.5 | 246 | 17 | 0 | 2 | 1 | 0 | 0 | 0 |
| INS | COL | 118 | 0 | 0 | 0 | 0 | 6.8 | 110 | 7 | 0 | 0 | 1 | 0 | 0 | 0 |
| | CRI | 35 | 0 | 0 | 0 | 1 | 0.0 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | ECU | 34 | 1 | 0 | 0 | 5 | 10.7 | 26 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| IPK | CUB | 21 | 16 | 0 | 0 | 0 | 0.0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ISP | CHL | 87 | 0 | 0 | 0 | 0 | 2.3 | 85 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| MAL | ARG ³ | 114 | 0 | 0 | 0 | 8 | 16.0 | 89 | 9 | 0 | 0 | 8 | 0 | 0 | 0 |
| | BOL | 41 | 4 | 0 | 0 | 0 | 16.2 | 31 | 5 | 0 | 0 | 1 | 0 | 0 | 0 |
| | URY | 1 | 0 | 0 | 0 | 0 | 0.0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | | 1455 | 154 | 8 | 0 | 38 | 10.3⁴ | 1127 | 92 | 3 | 3 | 22 | 0 | 0 | 0 |

¹ Cada muestra se refiere a un individuo

² Datos de México sólo del 2012 (13 de octubre)

³ Datos en revisión en el sistema ISIS.

⁴ Total excluye a México

Muestras de casos solamente

Cuadro No.2
Poliovirus con diferenciación intratípica (ITD)
Últimas 52 semanas (2011/42 - 2012/41)

| Lab. | País | Casos AFP con ITD | | | Poliovirus pendiente de ITD | | | | | | | | | | | | | |
|--------------|------|-------------------|-----------|--------------|-----------------------------|----------|----------|----------|---------------------|----------|----------|----------|---------------------|----------|----------|----------|----------|----------|
| | | ≤ 7days | Total | % | Aún no en el lab. | | | | En lab. < de 7 días | | | | En lab. > de 7 días | | | | Total | |
| | | | | | P1 | P2 | P3 | MIX | P1 | P2 | P3 | MIX | P1 | P2 | P3 | MIX | | |
| CAR | DOM | 0 | 1 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CAR | NIC | 0 | 0 | -- | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| FIO | BRA | 0 | 7 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| INS | COL | 0 | 1 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| INS | ECU | 0 | 1 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ISP | CHL | 0 | 1 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAL | ARG | 2 | 8 | 25.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAL | BOL | 0 | 1 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CDC | PRY | 1 | 1 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| INDRE | MEX | -- | 1 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2 |
| Total | | 3 | 22 | 13.00 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |

Muestras de casos solamente



Cuadro No.1
Casos de parálisis flácida aguda bajo investigación
Según semana de inicio de parálisis

| Sub Región | País | Total 2011 | Acum. 2012 | Semana | | | | | | | | | | | |
|--------------|--------|------------|------------|-----------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|----------|----------|----|
| | | | | 1-8 | 9-16 | 17-24 | 25-32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
| AND | BOL | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | |
| | COL | 0 | 10 | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 2 | 0 | 2 | |
| | ECU | 0 | 8 | 1 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| | PER | 2 | 7 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | |
| | VEN | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| BRA | BRA | 0 | 69 | 6 | 14 | 17 | 27 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | |
| CAP | CRI | 0 | 7 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | GTM | 0 | 3 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | HND | 0 | 12 | 0 | 0 | 0 | 8 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | |
| | NIC | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| | PAN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| CAR | SLV | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | CAR | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| LAC | CUB | 0 | 16 | 2 | 2 | 6 | 4 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | |
| | DOM | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | HTI | 0 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| MEX | MEX*** | 0 | 129 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| NOA | CAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| SOC | ARG | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | CHL | 0 | 20 | 0 | 0 | 0 | 6 | 4 | 4 | 0 | 2 | 1 | 2 | 1 | |
| | PRY | 0 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | |
| | URY | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| Total | | 2 | 304 | 12 | 26 | 28 | 58 | 11 | 9 | 9 | 6 | 4 | 8 | 2 | |

* Datos al 13 de octubre del 2012

Cuadro No.2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra adecuada y % de unidades notificando semanalmente

| Sub Región | País | Polio 2012 | | Casos PFA e Indicadores de últimas 52 semanas (2011/42 - 2012/41) | | | | % Unid. notificando | Polio 2011 | | Casos PFA e Indicadores 2011 (2011/01 - 2011/52) | | | | % Unid. notificando |
|----------------|------|------------|------------|---|-------------|--------------------|-------------|---------------------|------------|------------|--|-------------|--------------------|-------------|---------------------|
| | | Confirmado | Compatible | Casos | Tasa | % Invest. <48 hrs. | %1 Muestra+ | | Confirmado | Compatible | Casos | Tasa | % Invest. <48 hrs. | %1 Muestra+ | |
| AND | BOL | 0 | 0 | 41 | 1.13 | 90 | 88 | ... | 0 | 0 | 41 | 1.13 | 90 | 85 | ... |
| | COL | 0 | 0 | 128 | 0.98 | 51 | 80 | ... | 0 | 0 | 157 | 1.20 | 62 | 82 | 91 |
| | ECU | 0 | 0 | 38 | 0.84 | 39 | 71 | 48 | 0 | 0 | 39 | 0.88 | 31 | 72 | 86 |
| | PER | 0 | 0 | 102 | 1.22 | 87 | 74 | ... | 0 | 0 | 135 | 1.62 | 89 | 77 | 100 |
| | VEN | 0 | 0 | 68 | 0.79 | 94 | 76 | 61 | 0 | 0 | 71 | 0.83 | 72 | 85 | ... |
| BRA | BRA | 0 | 0 | 383 | 0.77 | 98 | 77 | ... | 0 | 1 | 561 | 1.13 | 97 | 76 | 95 |
| CAP | CRI | 0 | 0 | 23 | 2.01 | 52 | 91 | ... | 0 | 0 | 38 | 3.15 | 39 | 84 | ... |
| | GTM | 0 | 0 | 54 | 0.75 | 28 | 72 | 4 | 0 | 0 | 60 | 0.78 | 97 | 78 | ... |
| | HND | 0 | 0 | 68 | 2.20 | 100 | 87 | 93 | 0 | 0 | 63 | 2.07 | 100 | 92 | 92 |
| | NIC | 0 | 0 | 32 | 1.59 | 81 | 84 | 100 | 0 | 0 | 28 | 1.39 | 96 | 89 | 100 |
| | PAN | 0 | 0 | 7 | 0.70 | 76 | 71 | ... | 0 | 0 | 9 | 0.90 | ... | ... | 87 |
| CAR | SLV | 0 | 0 | 25 | 0.98 | 56 | 84 | ... | 0 | 0 | 59 | 2.44 | 51 | 78 | ... |
| | CAR | 0 | 0 | 25 | 0.30 | 84 | 28 | 67 | 0 | 0 | 26 | 0.59 | 77 | 12 | 66 |
| LAC | CUB | 0 | 0 | 21 | 1.04 | 100 | 95 | ... | 0 | 0 | 32 | 1.58 | 100 | 94 | 100 |
| | DOM | 0 | 0 | 22 | 0.67 | 45 | 86 | ... | 0 | 0 | 42 | 1.27 | 88 | 84 | 100 |
| | HTI | 0 | 0 | 4 | 0.07 | 50 | 75 | 66 | 0 | 0 | 10 | 0.17 | ... | 90 | ... |
| MEX | MEX | 0 | 0 | ... | ... | ... | ... | ... | 0 | 0 | 496 | 1.57 | 95 | 56 | 100 |
| NOA | CAN | 0 | 0 | 11 | 0.19 | 0 | 45 | ... | 0 | 0 | 40 | 0.70 | NR | 33 | NR |
| | USA | 0 | 0 | NR | NR | NR | NR | NR | 0 | 0 | NR | NR | NR | NR | NR |
| SOC | ARG | 0 | 0 | 112 | 1.07 | 44 | 80 | 123 | 0 | 0 | 172 | 1.68 | 31 | 83 | 107 |
| | CHL | 0 | 0 | 93 | 2.41 | 96 | 81 | ... | 0 | 0 | 89 | 2.30 | 96 | 85 | 100 |
| | PRY | 0 | 0 | 24 | 1.15 | 71 | 79 | ... | 0 | 0 | 18 | 0.90 | 56 | 67 | 93 |
| | URY | 0 | 0 | 1 | 0.13 | 0 | 0 | 1 | 0 | 0 | 9 | 1.17 | 11 | 67 | 4 |
| Total § | | 0 | 0 | 1282 | 0.76 | 74 | 78 | - | 0 | 1 | 2195 | 1.30 | 91 | 77 | 95 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis

... - Sin datos

CAR incluye informes de todos sus países miembros

§ Excluyendo EUA

NR - No reportando